Lenalidomid Stada Nord

Lenalidomide, the active ingredient in Lenalidomid Stada Nord, is an immunomodulatory drug presented as an oral formulation for oral use. It is used to treat certain blood cancers, specifically multiple myeloma and myelodysplastic syndromes, in adult patients.

GNH USA supplies Lenalidomid Stada Nord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant shipments to global markets.

Lenalidomide is indicated for hematologic malignancies and related bone‑marrow disorders.

- Multiple Myeloma (newly diagnosed): reduces disease progression and improves overall survival in adult patients. - Multiple Myeloma (relapsed/refractory): provides therapeutic benefit after prior treatment failure. - Myelodysplastic Syndromes with del(5q): decreases transfusion dependence and modifies disease course in eligible patients.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels leading to bleeding tendencies. - Fatigue: persistent tiredness affecting daily activities. - Nausea: upset stomach often occurring after dosing.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe skin reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

Before initiating therapy, clinicians should assess baseline parameters and monitor patients regularly.

- Blood count monitoring: perform routine CBC to detect neutropenia or thrombocytopenia. - Thromboembolic risk assessment: evaluate need for prophylactic anticoagulation in high‑risk patients. - Renal function evaluation: adjust therapy if creatinine clearance is impaired. - Pregnancy avoidance: ensure effective contraception and avoid use in pregnant women. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure. - Warfarin: concurrent use can potentiate anticoagulant effect and raise INR.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic levels. - P-glycoprotein substrates (e.g., digoxin): monitor for altered plasma concentrations. - Other immunomodulatory agents: increased risk of hematologic toxicity.